Prostate cancer progression after therapy of primary curative intent: A review of data from the prostate-specific antigen era

Mark Soloway, Mack Roach

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BACKGROUND. Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS. This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS. The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS. Improved and/or additional treatment options are needed for these patient groups.

Original languageEnglish
Pages (from-to)2310-2322
Number of pages13
JournalCancer
Volume104
Issue number11
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Disease Progression
Therapeutics
Neoplasm Grading
Prostatectomy
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Incidence
Neoplasms

Keywords

  • Brachytherapy
  • Disease progression
  • Disease stage
  • Gleason score
  • Prostate cancer
  • Prostate-specific antigen
  • Radical prostatectomy
  • RT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate cancer progression after therapy of primary curative intent : A review of data from the prostate-specific antigen era. / Soloway, Mark; Roach, Mack.

In: Cancer, Vol. 104, No. 11, 01.12.2005, p. 2310-2322.

Research output: Contribution to journalArticle

@article{ba9dd19c3e9441b394936dfd583f99f7,
title = "Prostate cancer progression after therapy of primary curative intent: A review of data from the prostate-specific antigen era",
abstract = "BACKGROUND. Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS. This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS. The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS. Improved and/or additional treatment options are needed for these patient groups.",
keywords = "Brachytherapy, Disease progression, Disease stage, Gleason score, Prostate cancer, Prostate-specific antigen, Radical prostatectomy, RT",
author = "Mark Soloway and Mack Roach",
year = "2005",
month = "12",
day = "1",
doi = "10.1002/cncr.21441",
language = "English",
volume = "104",
pages = "2310--2322",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Prostate cancer progression after therapy of primary curative intent

T2 - A review of data from the prostate-specific antigen era

AU - Soloway, Mark

AU - Roach, Mack

PY - 2005/12/1

Y1 - 2005/12/1

N2 - BACKGROUND. Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS. This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS. The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS. Improved and/or additional treatment options are needed for these patient groups.

AB - BACKGROUND. Radical prostatectomy and radiotherapy (RT), both radical therapies, are the standard treatments of curative intent for early prostate cancer. However, these therapies are not curative in all patients and, consequently, a substantial proportion of treated patients remain at risk of disease progression and/or cancer-related death. METHODS. This article presents contemporary data on the incidence of prostate-specific antigen (PSA) and clinical disease progression after primary therapy of curative intent in relation to commonly assessed pretreatment or pathologic disease characteristics. RESULTS. The data highlight the substantial risk of progression for certain patient groups, such as those with Gleason score 8-10, cT3 disease, lymph node metastases, and/or pretreatment PSA levels > 20 ng/mL. CONCLUSIONS. Improved and/or additional treatment options are needed for these patient groups.

KW - Brachytherapy

KW - Disease progression

KW - Disease stage

KW - Gleason score

KW - Prostate cancer

KW - Prostate-specific antigen

KW - Radical prostatectomy

KW - RT

UR - http://www.scopus.com/inward/record.url?scp=28044434387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28044434387&partnerID=8YFLogxK

U2 - 10.1002/cncr.21441

DO - 10.1002/cncr.21441

M3 - Article

C2 - 16222694

AN - SCOPUS:28044434387

VL - 104

SP - 2310

EP - 2322

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -